| Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in ... - MarketWatch (press release) |
|
|
MarketWatch (press release) The study, conducted by scientists at Cleveland Clinic, Roswell Park Cancer Institute and Hokkaido University, analyzed the ability of CBLB502 to attenuate injury in a murine model of acute ischemic renal failure, a potentially fatal and poorly |